Connable Office Inc. Purchases 1,585 Shares of Integer Holdings Co. (NYSE:ITGR)

Connable Office Inc. boosted its position in Integer Holdings Co. (NYSE:ITGR) by 28.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,100 shares of the medical equipment provider’s stock after purchasing an additional 1,585 shares during the quarter. Connable Office Inc.’s holdings in Integer were worth $941,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ITGR. Eagle Asset Management Inc. bought a new position in Integer in the third quarter worth about $14,403,000. Laurus Investment Counsel Inc. purchased a new stake in shares of Integer during the fourth quarter worth about $5,422,000. New York State Common Retirement Fund grew its stake in shares of Integer by 20.9% during the fourth quarter. New York State Common Retirement Fund now owns 232,569 shares of the medical equipment provider’s stock worth $30,820,000 after acquiring an additional 40,158 shares during the last quarter. Bamco Inc. NY grew its stake in shares of Integer by 17.4% during the third quarter. Bamco Inc. NY now owns 254,377 shares of the medical equipment provider’s stock worth $33,069,000 after acquiring an additional 37,700 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Integer by 23.3% during the third quarter. Jane Street Group LLC now owns 151,397 shares of the medical equipment provider’s stock worth $19,682,000 after acquiring an additional 28,572 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ITGR has been the topic of a number of research analyst reports. Oppenheimer lowered Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Truist Financial boosted their price target on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. KeyCorp boosted their price target on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Citigroup upped their target price on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company reiterated an “overweight” rating and issued a $160.00 target price on shares of Integer in a research report on Tuesday, December 3rd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $147.67.

Integer Trading Down 0.6 %

Shares of NYSE:ITGR opened at $123.01 on Friday. Integer Holdings Co. has a 12-month low of $107.11 and a 12-month high of $146.36. The company has a market capitalization of $4.14 billion, a PE ratio of 36.61, a PEG ratio of 1.72 and a beta of 1.13. The business has a 50 day moving average of $136.85 and a two-hundred day moving average of $132.83. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The company had revenue of $449.50 million during the quarter, compared to analyst estimates of $446.28 million. As a group, analysts forecast that Integer Holdings Co. will post 6.01 EPS for the current year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.